Advanced Breast Cancer

Advanced Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Strategies for Hormone Receptor-Positive Metastatic BC

January 21st 2020

EP. 2: CDK4/6 Inhibition in Hormone Receptor-Positive mBC

January 21st 2020

EP. 3: CtDNA Testing in Hormone Receptor-Positive mBC

January 21st 2020

EP. 4: Hormone Receptor-Positive mBC: Neoadjuvant Therapy

January 21st 2020

EP. 5: Approaching HER2 Testing in Breast Cancer

January 21st 2020

EP. 6: APHINITY Trial: Adjuvant HER2-Targeted Therapy in HER2+ BC

January 21st 2020

EP. 7: ATEMPT Trial: Stage I HER2+ Breast Cancer

January 21st 2020

EP. 8: Emerging Agents for Treatment of Advanced HER2+ BC

January 21st 2020

EP. 9: Advanced HER2+ BC: Phase III HER2CLIMB and DESTINY-Breast01

January 21st 2020

EP. 10: Treating HER2+ mBC: Immunotherapy and TKIs

January 21st 2020

EP. 11: IMpassion130 Trial: OS Updates in Metastatic TNBC

January 21st 2020

EP. 12: Key Trials in R/R Metastatic TNBC

January 21st 2020

EP. 13: Neoadjuvant Treatment for Triple-Negative Breast Cancer

January 21st 2020

EP. 14: Future Directions for Treatment of TNBC

January 21st 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma

Five Under 5: Top Oncology Videos for the Week of 8/31/26

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC